Spots Global Cancer Trial Database for Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study
Official Title: Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study
Study ID: NCT06202417
Interventions
Study Description
Brief Summary: Fruquintinib is an oral tyrosine kinase inhibitor (TKI), which improves progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC). Here, we explore the real-world treatment patterns of fruquintinib in the third- or late-line setting for mCRC in six centers in China.
Detailed Description:
Keywords
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Contact Details
Name: Jianmin Xu
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
